Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Enliven Therapeutics (NASDAQ:ELVN) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other research firms have also issued reports on ELVN. Zacks Research lowered Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 13th. William Blair initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating for the company. Morgan Stanley began coverage on shares of Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target on the stock. HC Wainwright raised their price target on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 19th. Finally, Barclays assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price objective on the stock. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Trading Up 10.4%

Shares of NASDAQ:ELVN opened at $49.43 on Friday. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32. The business’s fifty day simple moving average is $47.25 and its 200-day simple moving average is $43.08. The company has a market capitalization of $3.62 billion, a PE ratio of -28.91 and a beta of 0.34.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. Research analysts predict that Enliven Therapeutics will post -1.79 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer directly owned 38,000 shares in the company, valued at $1,462,240. The trade was a 13.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the transaction, the director directly owned 13,000 shares in the company, valued at $606,710. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 31,054 shares of company stock valued at $1,493,823 in the last three months. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its stake in shares of Enliven Therapeutics by 70.9% during the first quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock worth $26,714,000 after buying an additional 282,822 shares during the period. Legal & General Group Plc purchased a new stake in shares of Enliven Therapeutics during the second quarter valued at $1,671,000. Avidity Partners Management LP increased its position in shares of Enliven Therapeutics by 185.1% in the 1st quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock valued at $15,680,000 after acquiring an additional 259,700 shares during the period. Nicholas Investment Partners LP acquired a new position in shares of Enliven Therapeutics in the 2nd quarter valued at $19,870,000. Finally, Stempoint Capital LP acquired a new position in shares of Enliven Therapeutics in the 1st quarter valued at $14,247,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.